The direct oral anticoagulants (DOACs), including dabigatran, which is direct thrombin inhibitors, and apixaban, betrixaban, edoxaban, and rivaroxaban, which are direct factor Xa inhibitors, have been approved by the United States Food and Drug Administration (US FDA) for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF), prevention and treatment of venous thromboembolism (VTE), and secondary prevention of arterial ischemic events in patients with chronic coronary or peripheral artery disease [268–270]. The gene discussed is F10; the disease is venous thromboembolism.